Ghent University Academic Bibliography

Journal Article
A1
open access

Nucleic acid biomarkers in Waldenstrom Macroglobulinemia and IgM-MGUS : current insights and clinical relevance

Daniela Drandi, Philippe Decruyenaere (UGent) , Martina Ferrante, Fritz Offner (UGent) , Jo Vandesompele (UGent) and Simone Ferrero

(2022) DIAGNOSTICS. 12(4).

Add to list

Journal Article
A1
open access

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven E. Coutre, Stephen Devereux, et al.

(2020) LEUKEMIA. 34(3). p.787-798

Add to list

Journal Article
A1
open access

On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey (UGent) , Simon A. J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, et al.

(2020) MOLECULAR CANCER THERAPEUTICS. 19(2). p.468-478

Add to list

Journal Article
A1
open access

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

S. Degryse, C. E. de Bock, S. Demeyer, I. Govaerts, S. Bornschein, D. Verbeke, K. Jacobs, S. Binos, D. A. Skerrett-Byrne, H. C. Murray, et al.

(2018) LEUKEMIA. 32(3). p.788-800

Add to list

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2018) BLOOD. 132(23). p.2446-2455

Add to list

Analysis of DNA methylation in cancer : location revisited

Alexander Koch, Sophie C Joosten, Zheng Feng, Tim C de Ruijter, Muriel X Draht, Veerle Melotte, Kim M Smits, Jurgen Veeck, James G Herman, Leander Van Neste, et al.

(2018) NATURE REVIEWS CLINICAL ONCOLOGY. 15(7). p.459-466

Add to list

Journal Article
A1
open access

Analysis of circulating microRNAs and their post-transcriptional modifications in cancer serum by on-line solid-phase extraction-capillary electrophoresis-mass spectrometry

Roger Peró Gascón (UGent) , Victoria Sanz-Nebot, Maxim V. Berezovski and Fernando Benavente

(2018) ANALYTICAL CHEMISTRY. 90(11). p.6618-6625

Add to list

Journal Article
A1
open access

Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia

Anne Benard-Slagter, Ilse Zondervan, Karel de Groot, Farzaneh Ghazavi (UGent) , Virinder Sarhadi, Pieter Van Vlierberghe (UGent) , Barbara De Moerloose (UGent) , Claire Schwab, Kim Vettenranta, Christine J Harrison, et al.

(2017) JOURNAL OF MOLECULAR DIAGNOSTICS. 19(5). p.659-672

Add to list

Long non-coding RNAs in leukemia : biology and clinical impact

Tim Lammens (UGent) , Kaat Durinck (UGent) , Annelynn Wallaert (UGent) , Franki Speleman (UGent) and Pieter Van Vlierberghe (UGent)

(2017) CURRENT OPINION IN HEMATOLOGY. 24(4). p.353-358

Add to list

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey (UGent) , Fritz Offner (UGent) , Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, et al.

(2017) CLINICAL CANCER RESEARCH. 23(21). p.6411-6420

Academic Bibliography

Nucleic acid biomarkers in Waldenstrom Macroglobulinemia and IgM-MGUS : current insights and clinical relevance

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study

On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Analysis of DNA methylation in cancer : location revisited

Analysis of circulating microRNAs and their post-transcriptional modifications in cancer serum by on-line solid-phase extraction-capillary electrophoresis-mass spectrometry

Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia

Long non-coding RNAs in leukemia : biology and clinical impact

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Contents

Support

Contact